CN112382362A - Data analysis method and device for target drugs - Google Patents
Data analysis method and device for target drugs Download PDFInfo
- Publication number
- CN112382362A CN112382362A CN202011219306.8A CN202011219306A CN112382362A CN 112382362 A CN112382362 A CN 112382362A CN 202011219306 A CN202011219306 A CN 202011219306A CN 112382362 A CN112382362 A CN 112382362A
- Authority
- CN
- China
- Prior art keywords
- information
- target
- drug
- indication
- research
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Theoretical Computer Science (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Public Health (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
The embodiment of the invention provides a data analysis method and device for a target drug. Wherein, the method comprises the following steps: acquiring a target point query request; according to the target point and a preset relation map, acquiring medicine information corresponding to the target point, and indication information corresponding to the medicine information and a research and development stage of the medicine information; sorting the medicine information and the indication information according to a preset weight value at intervals of a preset time interval to obtain corresponding sorting order difference values; and determining the clinical indication development progress information of the medicines corresponding to the target point according to the sorting order difference value. By adopting the data analysis method for the target point medicine disclosed by the embodiment of the invention, the clinical indication research and development progress data of different medicines at each target point can be updated in real time, the data analysis efficiency is greatly improved, and the use experience of a user is effectively improved.
Description
Technical Field
The invention relates to the technical field of computer application, in particular to a data analysis method and device for a target drug. In addition, an electronic device and a non-transitory computer readable storage medium are also related.
Background
The drug target refers to the action binding site of the drug in vivo, and comprises biological macromolecules such as gene sites, receptors, enzymes, ion channels, nucleic acids and the like. The key of modern new drug research and development is to find, determine and prepare drug screening targets. How to quickly acquire the development progress information and the variation trend of clinical indications of different drugs under a target point by inquiring a drug target point becomes a key point of attention of people.
At present, the information of research and development indications of each drug under the same target spot is analyzed and mined traditionally, and is generally obtained through manual arrangement of multi-channel data such as enterprise bulletins, information, official networks and the like, and the statistical analysis mode is time-consuming and labor-consuming and is easy to have data loss. Therefore, how to quickly and effectively perform data collection, statistics and analysis on clinical indication development data of different drugs under a target point becomes a problem to be solved in the industry at present.
Disclosure of Invention
Therefore, the embodiment of the invention provides a data analysis method and device for a target drug, so as to solve the problems that the statistical analysis method in the prior art is time-consuming and labor-consuming, and data loss is easy to occur, so that the user experience is poor.
In a first aspect, an embodiment of the present invention provides a data analysis method for a target drug, including:
acquiring a target point query request;
according to the target point and a preset relation map, acquiring medicine information corresponding to the target point, and indication information corresponding to the medicine information and a research and development stage of the medicine information;
setting corresponding weight values aiming at each research and development stage respectively;
sorting the medicine information and the indication information according to the weight values at preset time intervals to obtain corresponding sorting order difference values;
and determining the clinical indication development progress information of the medicines corresponding to the target point according to the sorting order difference value.
Further, the acquiring, according to the target point and a preset relationship map, the drug information corresponding to the target point, and the indication information corresponding to the drug information and the research and development stage thereof specifically include:
acquiring a first medicine information set corresponding to the target point according to the target point and a preset relation map of the target point and the medicine information;
acquiring an indication information set corresponding to each drug information in the first drug information set according to a preset relationship graph of the drug information and the indication information, and determining a second drug information set corresponding to each indication in the indication information set; wherein the second set of drug information is a subset of the first set of drug information;
and acquiring a research and development stage information set corresponding to each drug information according to the indication information set, the second drug information set and a preset relationship map among the drug information, the indication information and the research and development stages, and acquiring a research and development stage information set corresponding to each indication.
Further, the sorting the medicine information and the indication information according to the weight value at preset time intervals to obtain corresponding sorting order difference specifically includes:
summing the weighted values of the information sets in the research and development stages corresponding to each kind of medicine information at intervals of preset time to obtain a first target weighted value; sorting the medicine information according to the first target weight value to obtain sorting order difference values corresponding to the medicine information respectively; and the number of the first and second groups,
summing the weighted values of the acquired information sets in the research and development stage corresponding to each indication at intervals of preset time to obtain a second target weighted value; and sorting the indication information according to the size of the second target weight value to obtain sorting order difference values corresponding to the indication information respectively.
Further, the data analysis method for the target drug further comprises:
generating a basic table based on the medicine information, the indication information corresponding to the medicine information and the research and development stage of the indication information;
setting corresponding weight values for each research and development stage in the basic table respectively to generate a secondary table; the secondary table contains the drug information, the indication information, the development stage and the weight value thereof;
and sorting the medicine information and the indication information according to the weight values in the secondary table at preset time intervals to generate a target table.
Further, the development phase comprises: preclinical, declared clinical, phase I/II clinical, phase II/III clinical, phase III/IV clinical, phase IV clinical, application marketing, and approval marketing.
In a second aspect, an embodiment of the present invention further provides a data analysis apparatus for a target drug, including:
the request acquisition unit is used for acquiring a target point query request;
the target information acquisition unit is used for acquiring medicine information corresponding to the target point, and indication information corresponding to the medicine information and a research and development stage of the medicine information according to the target point and a preset relation map;
the weight setting unit is used for setting corresponding weight values aiming at each research and development stage respectively;
the sorting unit is used for sorting the medicine information and the indication information according to the weight values at intervals of preset time to obtain corresponding sorting order difference values;
and the data analysis unit is used for determining the clinical indication development progress information of the medicines corresponding to the target point according to the sorting order difference value.
Further, the target information obtaining unit is specifically configured to:
acquiring a first medicine information set corresponding to the target point according to the target point and a preset relation map of the target point and the medicine information;
acquiring an indication information set corresponding to each drug information in the first drug information set according to a preset relationship graph of the drug information and the indication information, and determining a second drug information set corresponding to each indication in the indication information set; wherein the second set of drug information is a subset of the first set of drug information;
and acquiring a research and development stage information set corresponding to each drug information according to the indication information set, the second drug information set and a preset relationship map among the drug information, the indication information and the research and development stages, and acquiring a research and development stage information set corresponding to each indication.
Further, the sorting unit is specifically configured to:
summing the weighted values of the information sets in the research and development stages corresponding to each kind of medicine information at intervals of preset time to obtain a first target weighted value; sorting the medicine information according to the first target weight value to obtain sorting order difference values corresponding to the medicine information respectively; and the number of the first and second groups,
summing the weighted values of the acquired information sets in the research and development stage corresponding to each indication at intervals of preset time to obtain a second target weighted value; and sorting the indication information according to the size of the second target weight value to obtain sorting order difference values corresponding to the indication information respectively.
Further, the data analysis device for target drugs further comprises:
a basic table generating unit, configured to generate a basic table based on the drug information, the indication information corresponding to the drug information, and the research and development stage of the indication information;
the secondary table generating unit is used for setting corresponding weight values for all research and development stages in the basic table respectively to generate a secondary table; the secondary table contains the drug information, the indication information, the development stage and the weight value thereof;
and the target table generating unit is used for sorting the medicine information and the indication information according to the weight values in the secondary table at preset time intervals to generate a target table.
Further, the development phase comprises: preclinical, declared clinical, phase I/II clinical, phase II/III clinical, phase III/IV clinical, phase IV clinical, application marketing, and approval marketing.
In a third aspect, an embodiment of the present invention further provides an electronic device, including: a memory, a processor and a computer program stored on the memory and executable on the processor, the processor implementing the steps of the data analysis method for a target drug as described in any one of the above when executing the program.
In a fourth aspect, embodiments of the present invention further provide a non-transitory computer readable storage medium, on which a computer program is stored, the computer program, when executed by a processor, implementing the steps of the data analysis method for a target drug as described in any one of the above.
By adopting the data analysis method for the target point drugs, the drugs corresponding to the target points and the data of the indications of the drugs are sequenced through the weight set in the research and development stage, the research and development conditions of the clinical indications of different drugs at each target point are accurately obtained through recalculating the sequencing sequence difference value in the preset time interval, the change trend of the clinical test is reflected in time, the user can quickly obtain the research and development progress information of the clinical indications of different drugs at the target point, the data is updated in real time, the research and development data analysis efficiency is greatly improved, and the comprehensiveness and the accuracy of the data are also greatly improved.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to these drawings without creative efforts.
Fig. 1 is a schematic flow chart of a data analysis method for a target drug according to an embodiment of the present invention;
fig. 2 is a schematic structural diagram of a data analysis device for a target drug according to an embodiment of the present invention;
fig. 3 is a schematic physical structure diagram of an electronic device according to an embodiment of the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are some, but not all, embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The following describes embodiments of the data analysis method for target drugs according to the present invention in detail. As shown in fig. 1, which is a flowchart of a data analysis method for a target drug provided in an embodiment of the present invention, a specific implementation process includes the following steps:
step S101: and acquiring a target point query request.
Specifically, the target site is a drug target site, which refers to a binding site of a drug and a biological macromolecule of an organism, such as a pdi (protein disulide isomerase) target site.
In the embodiment of the invention, before the target point query request is acquired, a knowledge graph of the drug information and the target point information and the standardized indication data need to be established in advance, the drug information and the clinical data are associated, and a relation graph containing the drug information, the target point information, the indication information, the corresponding research and development stage information and the like is constructed.
Step S102: and acquiring medicine information corresponding to the target point, indication information corresponding to the medicine information and a research and development stage of the indication information according to the target point and a preset relation map.
In this step, the drug information corresponding to the target point, and the indication information corresponding to the drug information and the research and development stage thereof are obtained according to the target point and a preset relationship map, and the specific implementation process includes: and acquiring a first medicine information set corresponding to the target point according to the input target point and a preset relation map of the target point and the medicine information. For example, the inputted target point is a PDI target point, and the corresponding first drug information set may include palivizumab, nivolumetrizumab, carleyizumab, terieprituril mab, and the like. By taking each medicine in the first medicine information set as an index, according to a preset relation graph of medicine information and indication information, an indication information set corresponding to each kind of medicine information in the first medicine information set can be obtained, and a second medicine information set corresponding to each kind of indication in the indication information set is determined. Wherein the second set of drug information is a subset of the first set of drug information. In correspondence with the above PDI targets and listed drugs, the set of indication information may include: non-small cell lung cancer, solid tumors, gastric cancer, and the like. The second drug information set corresponding to each indication in the indication information set corresponds to a part of the content in the first drug information set, for example, the second drug information set corresponding to the non-small cell lung cancer indication includes the palbociclumab, the niuliuzumab and the carrayleigh mab in the first drug information set.
Further, according to the indication information set, the second medicine information set, preset medicine information, indication information and a relationship map among research and development phases, a research and development phase information set corresponding to each kind of medicine information can be obtained, and a research and development phase information set corresponding to each kind of indication can be obtained. Wherein the development phase comprises: the research and development stages of preclinical, declaration clinical, phase I/II clinical, phase II/III clinical, phase III/IV clinical, phase IV clinical, application marketing and approval marketing, etc.
In a specific implementation process, based on the drug information, the indication information corresponding to the drug information and the development stage thereof, a basic table for recording m × n of the information is generated, and each element in the table records the corresponding development stage.
Step S103: and setting corresponding weight values for each research and development stage.
In step, a corresponding weight value may be further set for each development stage in the basic table, so as to generate a corresponding secondary table. The secondary table contains the drug information, the indication information, the development stage and the weight value thereof, and the like.
Specifically, after the research and development stages are given weights one by one, along with the progress of the research and development stages, the weight values corresponding to the research and development stages may be gradually increased, for example, the probability that the conversion upgrade is successful or failed in each research and development stage is preset to be 50%, so that the weight difference between two adjacent research and development stages is set to be 0.5, and a secondary table of m × n is generated. For example, for preclinical, declared clinical, phase I/II clinical, phase II/III clinical, phase III/IV clinical, phase IV clinical, application marketing, and approval marketing, the corresponding weights for each development phase are set to 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, and 5.5, respectively.
The weighting rules according to the present invention are not limited to the above-mentioned examples, and may be changed as needed during the implementation process, and are not specifically limited herein
Step S104: and sorting the medicine information and the indication information according to the weight values at preset time intervals to obtain corresponding sorting order difference values.
In this step, the medicine information and the indication information are sorted according to the weight value at preset time intervals to obtain corresponding sorting order difference values, and the specific implementation process includes: summing the weighted values of the development stage information sets corresponding to each type of medicine information at preset time intervals to obtain a first target weighted value, and sorting the medicine information according to the first target weighted value to obtain sorting order difference values corresponding to the medicine information respectively; and summing the weighted values of the acquired research and development stage information sets corresponding to each type of indication at intervals of preset time to obtain a second target weighted value, and sorting the indication information according to the size of the second target weighted value to obtain sorting order difference values corresponding to the indication information respectively.
As shown in the following table 1.1 and table 1.2, which are the generated secondary table and the generated target table reordered after a preset time interval, respectively.
In a specific implementation process, the row sorting of the drug information and the column sorting of the indication information may be performed on the generated secondary table at preset time intervals, for example, every month, that is, the drug information and the indication information are sorted according to the sum of the weight values of the corresponding development phase sets, and the specific sorting manner may be: and performing descending arrangement according to the medicine information of each row or the sum of the weights of the development stage sets corresponding to the indications of each column to generate a target table.
| Serial number | Variations in | Indications of | Name of drug 1 | Name of drug 2 | Name of drug 3 | Name of drug 4 |
| 1 | Indication 1 | Approved for marketing | Application for marketing | Stage III/IV clinics | Phase II/III clinics | |
| 2 | Indication 2 | Approved for marketing | Application for marketing | Stage III/IV clinics | Stage II clinics | |
| 3 | Indication 3 | Approved for marketing | Stage IV clinics | Stage III clinics | Stage I clinics | |
| 4 | Indication 4 | Application for marketing | Stage III/IV clinics | Phase II/III clinics | Before clinical treatment |
TABLE 1.1
TABLE 1.2
Step S105: and determining the clinical indication development progress information of the medicines corresponding to the target point according to the sorting order difference value.
Specifically, if the sorting order difference value corresponding to the indication is a negative value, it indicates that the clinical indication development progress of the drug corresponding to the target point is slow, and at this time, the larger the absolute value of the difference value is, the slower the clinical indication development progress speed of the drug is; if the sorting order difference value corresponding to the indication is a positive value, the clinical indication development progress of the medicine corresponding to the target point is fast or the medicines under study are more, and at the moment, the larger the absolute value of the difference value is, the faster the clinical indication development progress speed of the medicine is or the medicines under study are more. If the sorting order difference value corresponding to the medicines is a negative value, the research and development progress of the medicines corresponding to the target point is slow or the research and development failure of clinical indications disappears, and at the moment, the larger the absolute value of the difference value is, the slower the research and development speed of the medicines is or the more the research and development failure of the indications is; if the sorting order difference value corresponding to the medicines is a positive value, the research and development progress of the medicines corresponding to the target point is fast or the research and development of clinical indications are increased, and at the moment, the larger the absolute value of the difference value is, the faster the research and development progress of the medicines is or the more clinical indications are increased.
By adopting the data analysis method for the target drugs, provided by the embodiment of the invention, the drugs corresponding to the target and the data of the indications of the drugs are sequenced through the weight set in the research and development stage, the research and development conditions of the clinical indications of different drugs at each target are accurately obtained through recalculating the sequencing sequence difference value in the preset time interval, the change trend of the clinical test is reflected in time, the user can quickly obtain the research and development progress information of the clinical indications of different drugs at the target, the change trend and the success probability of the clinical test can be comprehensively and timely reflected, the user can accurately and intuitively obtain the research and development progress information of the clinical indications of different drugs at the target, the research and development data analysis efficiency is greatly improved, and the comprehensiveness and the accuracy of the data are also greatly improved.
Corresponding to the data analysis method for the target medicine, the invention also provides a data analysis device for the target medicine. Since the embodiment of the device is similar to the above method embodiment, the description is simple, and please refer to the description in the above method embodiment, and the following embodiments of the data analysis device for target drugs are only schematic. Fig. 2 is a schematic structural diagram of a data analysis apparatus for a target drug according to an embodiment of the present invention.
The data analysis device for the target medicine specifically comprises the following parts:
a request obtaining unit 201, configured to obtain a target query request.
The target information obtaining unit 202 is configured to obtain, according to the target point and a preset relationship map, medicine information corresponding to the target point, and indication information corresponding to the medicine information and a research and development stage of the medicine information.
A weight setting unit 203, configured to set corresponding weight values for each development stage.
And the sorting unit 204 is configured to sort the medicine information and the indication information according to the weight value at preset time intervals to obtain corresponding sorting order difference values.
And the data analysis unit 205 is configured to determine clinical indication development progress information of the drug corresponding to the target point according to the sorting order difference.
By adopting the data analysis device for the target drugs, provided by the embodiment of the invention, the drugs and the indication data corresponding to the target are sequenced through the weight set in the research and development stage, the research and development conditions of the clinical indications of different drugs at each target are accurately obtained through recalculating the sequencing sequence difference value in the preset time interval, the change trend of the clinical test is reflected in time, the user can quickly obtain the research and development progress information of the clinical indications of different drugs at the target, the change trend and the success probability of the clinical test can be comprehensively and timely reflected, the user can accurately and visually obtain the research and development progress information of the clinical indications of different drugs at the target, the research and development data analysis efficiency is greatly improved, and the comprehensiveness and the accuracy of the data are also greatly improved.
Corresponding to the data analysis method for the target drugs, the invention also provides electronic equipment. Since the embodiment of the electronic device is similar to the above method embodiment, the description is relatively simple, and please refer to the description of the above method embodiment, and the electronic device described below is only schematic. Fig. 3 is a schematic physical structure diagram of an electronic device according to an embodiment of the present invention. The electronic device may include: a processor (processor)301, a memory (memory)302 and a communication bus 303, wherein the processor 301 and the memory 302 communicate with each other via the communication bus 303. The processor 301 may invoke logic instructions in the memory 302 to perform a method of data analysis for a target drug, the method comprising: acquiring a target point query request; according to the target point and a preset relation map, acquiring medicine information corresponding to the target point, and indication information corresponding to the medicine information and a research and development stage of the medicine information; setting corresponding weight values aiming at each research and development stage respectively; sorting the medicine information and the indication information according to the weight values at preset time intervals to obtain corresponding sorting order difference values; and determining the clinical indication development progress information of the medicines corresponding to the target point according to the sorting order difference value.
Furthermore, the logic instructions in the memory 302 may be implemented in software functional units and stored in a computer readable storage medium when sold or used as a stand-alone product. Based on such understanding, the technical solution of the present invention may be embodied in the form of a software product, which is stored in a storage medium and includes instructions for causing a computer device (which may be a personal computer, a server, or a network device) to execute all or part of the steps of the method according to the embodiments of the present invention. And the aforementioned storage medium includes: a U-disk, a removable hard disk, a Read-Only Memory (ROM), a Random Access Memory (RAM), a magnetic disk or an optical disk, and other various media capable of storing program codes.
In another aspect, an embodiment of the present invention further provides a computer program product, which includes a computer program stored on a non-transitory computer-readable storage medium, the computer program including program instructions, when the program instructions are executed by a computer, the computer being capable of executing the data analysis method for a target drug provided by the above-mentioned method embodiments, the method including: according to the target point and a preset relation map, acquiring medicine information corresponding to the target point, and indication information corresponding to the medicine information and a research and development stage of the medicine information; setting corresponding weight values aiming at each research and development stage respectively; sorting the medicine information and the indication information according to the weight values at preset time intervals to obtain corresponding sorting order difference values; and determining the clinical indication development progress information of the medicines corresponding to the target point according to the sorting order difference value.
In yet another aspect, an embodiment of the present invention further provides a non-transitory computer-readable storage medium, on which a computer program is stored, the computer program being implemented by a processor to perform the data analysis method for a target drug provided in the foregoing embodiments, the method including: according to the target point and a preset relation map, acquiring medicine information corresponding to the target point, and indication information corresponding to the medicine information and a research and development stage of the medicine information; setting corresponding weight values aiming at each research and development stage respectively; sorting the medicine information and the indication information according to the weight values at preset time intervals to obtain corresponding sorting order difference values; and determining the clinical indication development progress information of the medicines corresponding to the target point according to the sorting order difference value.
The above-described embodiments of the apparatus are merely illustrative, and the units described as separate parts may or may not be physically separate, and parts displayed as units may or may not be physical units, may be located in one place, or may be distributed on a plurality of network units. Some or all of the modules may be selected according to actual needs to achieve the purpose of the solution of the present embodiment. One of ordinary skill in the art can understand and implement it without inventive effort.
Through the above description of the embodiments, those skilled in the art will clearly understand that each embodiment can be implemented by software plus a necessary general hardware platform, and certainly can also be implemented by hardware. With this understanding in mind, the above-described technical solutions may be embodied in the form of a software product, which can be stored in a computer-readable storage medium such as ROM/RAM, magnetic disk, optical disk, etc., and includes instructions for causing a computer device (which may be a personal computer, a server, or a network device, etc.) to execute the methods described in the embodiments or some parts of the embodiments.
Finally, it should be noted that: the above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.
Claims (10)
1. A method for analyzing data for a target drug, comprising:
acquiring a target point query request;
according to the target point and a preset relation map, acquiring medicine information corresponding to the target point, and indication information corresponding to the medicine information and a research and development stage of the medicine information;
setting corresponding weight values aiming at each research and development stage respectively;
sorting the medicine information and the indication information according to the weight values at preset time intervals to obtain corresponding sorting order difference values;
and determining the clinical indication development progress information of the medicines corresponding to the target point according to the sorting order difference value.
2. The data analysis method for the target drug according to claim 1, wherein the acquiring, according to the target and a preset relationship map, the drug information corresponding to the target, the indication information corresponding to the drug information, and the development stage thereof specifically includes:
acquiring a first medicine information set corresponding to the target point according to the target point and a preset relation map of the target point and the medicine information;
acquiring an indication information set corresponding to each drug information in the first drug information set according to a preset relationship graph of the drug information and the indication information, and determining a second drug information set corresponding to each indication in the indication information set; wherein the second set of drug information is a subset of the first set of drug information;
and acquiring a research and development stage information set corresponding to each drug information according to the indication information set, the second drug information set and a preset relationship map among the drug information, the indication information and the research and development stages, and acquiring a research and development stage information set corresponding to each indication.
3. The target drug-specific data analysis method according to claim 2, wherein the sorting the drug information and the indication information according to the weight value at preset time intervals to obtain corresponding sorting order differences specifically comprises:
summing the weighted values of the information sets in the research and development stages corresponding to each kind of medicine information at intervals of preset time to obtain a first target weighted value; sorting the medicine information according to the first target weight value to obtain sorting order difference values corresponding to the medicine information respectively; and summing the weighted values of the acquired research and development stage information sets corresponding to each indication at preset time intervals to obtain a second target weighted value; and sorting the indication information according to the size of the second target weight value to obtain sorting order difference values corresponding to the indication information respectively.
4. The method for analyzing data on a target drug according to claim 1, further comprising:
generating a basic table based on the medicine information, the indication information corresponding to the medicine information and the research and development stage of the indication information;
setting corresponding weight values for each research and development stage in the basic table respectively to generate a secondary table; the secondary table contains the drug information, the indication information, the development stage and the weight value thereof;
and sorting the medicine information and the indication information according to the weight values in the secondary table at preset time intervals to generate a target table.
5. The method for data analysis of a target drug according to any one of claims 1-4, wherein the development phase comprises: preclinical, declared clinical, phase I/II clinical, phase II/III clinical, phase III/IV clinical, phase IV clinical, application marketing, and approval marketing.
6. A data analysis device for a target drug, comprising:
the request acquisition unit is used for acquiring a target point query request;
the target information acquisition unit is used for acquiring medicine information corresponding to the target point, and indication information corresponding to the medicine information and a research and development stage of the medicine information according to the target point and a preset relation map;
the weight setting unit is used for setting corresponding weight values aiming at each research and development stage respectively;
the sorting unit is used for sorting the medicine information and the indication information according to the weight values at intervals of preset time to obtain corresponding sorting order difference values;
and the data analysis unit is used for determining the clinical indication development progress information of the medicines corresponding to the target point according to the sorting order difference value.
7. The target drug-directed data analysis device of claim 6, wherein the target information acquisition unit is specifically configured to:
acquiring a first medicine information set corresponding to the target point according to the target point and a preset relation map of the target point and the medicine information;
acquiring an indication information set corresponding to each drug information in the first drug information set according to a preset relationship graph of the drug information and the indication information, and determining a second drug information set corresponding to each indication in the indication information set; wherein the second set of drug information is a subset of the first set of drug information;
and acquiring a research and development stage information set corresponding to each drug information according to the indication information set, the second drug information set and a preset relationship map among the drug information, the indication information and the research and development stages, and acquiring a research and development stage information set corresponding to each indication.
8. The target drug-directed data analysis method of claim 7, wherein the ranking unit is specifically configured to:
summing the weighted values of the information sets in the research and development stages corresponding to each kind of medicine information at intervals of preset time to obtain a first target weighted value; sorting the medicine information according to the first target weight value to obtain sorting order difference values corresponding to the medicine information respectively; and summing the weighted values of the acquired research and development stage information sets corresponding to each indication at preset time intervals to obtain a second target weighted value; and sorting the indication information according to the size of the second target weight value to obtain sorting order difference values corresponding to the indication information respectively.
9. An electronic device comprising a memory, a processor and a computer program stored on the memory and executable on the processor, wherein the processor when executing the program performs the steps of the method for data analysis of a target drug according to any one of claims 1-5.
10. A non-transitory computer readable storage medium, having a computer program stored thereon, wherein the computer program, when executed by a processor, implements the steps of the method for data analysis of a target drug according to any one of claims 1-5.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011219306.8A CN112382362B (en) | 2020-11-04 | 2020-11-04 | Data analysis method and device for target drugs |
| PCT/CN2021/128305 WO2022095870A1 (en) | 2020-11-04 | 2021-11-03 | Method and apparatus for analyzing data of target drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011219306.8A CN112382362B (en) | 2020-11-04 | 2020-11-04 | Data analysis method and device for target drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112382362A true CN112382362A (en) | 2021-02-19 |
| CN112382362B CN112382362B (en) | 2021-06-29 |
Family
ID=74578296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011219306.8A Active CN112382362B (en) | 2020-11-04 | 2020-11-04 | Data analysis method and device for target drugs |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN112382362B (en) |
| WO (1) | WO2022095870A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113539515A (en) * | 2021-07-01 | 2021-10-22 | 上海药慧信息技术有限公司 | Clinical demand mining method and device, electronic equipment and storage medium |
| CN114255877A (en) * | 2021-12-06 | 2022-03-29 | 北京华彬立成科技有限公司 | Target point information mining and searching method and device, electronic equipment and storage medium |
| WO2022095870A1 (en) * | 2020-11-04 | 2022-05-12 | 北京华彬立成科技有限公司 | Method and apparatus for analyzing data of target drug |
| CN114927232A (en) * | 2022-04-29 | 2022-08-19 | 数魔方(北京)医药科技有限公司 | Drug research and development type mining and searching method and device and electronic equipment |
| CN115019976A (en) * | 2022-03-23 | 2022-09-06 | 数魔方(北京)医药科技有限公司 | Medicine information mining method and device, and medicine information query method and device |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114841680B (en) * | 2022-06-30 | 2022-10-04 | 汇通达网络股份有限公司 | Research and development management method, device and equipment for online shopping mall and readable storage medium |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102222178A (en) * | 2011-03-31 | 2011-10-19 | 清华大学深圳研究生院 | Method for screening and/or designing medicines aiming at multiple targets |
| CN102663214A (en) * | 2012-05-09 | 2012-09-12 | 四川大学 | Construction and prediction method of integrated drug target prediction system |
| US20170154163A1 (en) * | 2015-12-01 | 2017-06-01 | Ramot At Tel-Aviv University Ltd. | Clinically relevant synthetic lethality based method and system for cancer prognosis and therapy |
| US20170329892A1 (en) * | 2016-05-10 | 2017-11-16 | Accutar Biotechnology Inc. | Computational method for classifying and predicting protein side chain conformations |
| CN107633153A (en) * | 2017-08-22 | 2018-01-26 | 深圳华大基因研究院 | A kind of method and system of tumour individuation clinical trial text mining |
| CN109074420A (en) * | 2016-05-12 | 2018-12-21 | 豪夫迈·罗氏有限公司 | System for predicting the effect of targeted drug treatment disease |
| CN109493925A (en) * | 2018-11-20 | 2019-03-19 | 北京晶派科技有限公司 | A kind of method of determining drug and drug target incidence relation |
| CN110880354A (en) * | 2019-10-24 | 2020-03-13 | 广东药科大学 | Medicine-target interaction prediction method based on group intelligence |
| CN111191014A (en) * | 2019-12-26 | 2020-05-22 | 上海科技发展有限公司 | Medicine relocation method, system, terminal and medium |
| CN111696685A (en) * | 2020-06-04 | 2020-09-22 | 大连理工大学 | Medicine repositioning method for new coronavirus treatment medicine and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11798689B2 (en) * | 2016-07-25 | 2023-10-24 | Viecure, Inc. | Generating customizable personal healthcare treatment plans |
| CN112382362B (en) * | 2020-11-04 | 2021-06-29 | 北京华彬立成科技有限公司 | Data analysis method and device for target drugs |
-
2020
- 2020-11-04 CN CN202011219306.8A patent/CN112382362B/en active Active
-
2021
- 2021-11-03 WO PCT/CN2021/128305 patent/WO2022095870A1/en active Application Filing
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102222178A (en) * | 2011-03-31 | 2011-10-19 | 清华大学深圳研究生院 | Method for screening and/or designing medicines aiming at multiple targets |
| CN102663214A (en) * | 2012-05-09 | 2012-09-12 | 四川大学 | Construction and prediction method of integrated drug target prediction system |
| US20170154163A1 (en) * | 2015-12-01 | 2017-06-01 | Ramot At Tel-Aviv University Ltd. | Clinically relevant synthetic lethality based method and system for cancer prognosis and therapy |
| US20170329892A1 (en) * | 2016-05-10 | 2017-11-16 | Accutar Biotechnology Inc. | Computational method for classifying and predicting protein side chain conformations |
| CN109074420A (en) * | 2016-05-12 | 2018-12-21 | 豪夫迈·罗氏有限公司 | System for predicting the effect of targeted drug treatment disease |
| CN107633153A (en) * | 2017-08-22 | 2018-01-26 | 深圳华大基因研究院 | A kind of method and system of tumour individuation clinical trial text mining |
| CN109493925A (en) * | 2018-11-20 | 2019-03-19 | 北京晶派科技有限公司 | A kind of method of determining drug and drug target incidence relation |
| CN110880354A (en) * | 2019-10-24 | 2020-03-13 | 广东药科大学 | Medicine-target interaction prediction method based on group intelligence |
| CN111191014A (en) * | 2019-12-26 | 2020-05-22 | 上海科技发展有限公司 | Medicine relocation method, system, terminal and medium |
| CN111696685A (en) * | 2020-06-04 | 2020-09-22 | 大连理工大学 | Medicine repositioning method for new coronavirus treatment medicine and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| QICHANG ZHAO 等: "AttentionDTA: prediction of drug–target binding affinity using attention model", 《2019 IEEE INTERNATIONAL CONFERENCE ON BIOINFORMATICS AND BIOMEDICINE (BIBM)》 * |
| 付婷婷: "G公司上海研发中心临床前新药研发项目评估方法的研究", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》 * |
| 王亚飞 等: "靶向药物全球同步研发设计中的统计学性能比较", 《中国临床药理学与治疗学》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022095870A1 (en) * | 2020-11-04 | 2022-05-12 | 北京华彬立成科技有限公司 | Method and apparatus for analyzing data of target drug |
| CN113539515A (en) * | 2021-07-01 | 2021-10-22 | 上海药慧信息技术有限公司 | Clinical demand mining method and device, electronic equipment and storage medium |
| CN113539515B (en) * | 2021-07-01 | 2023-03-21 | 上海药慧信息技术有限公司 | Clinical demand mining method and device, electronic equipment and storage medium |
| CN114255877A (en) * | 2021-12-06 | 2022-03-29 | 北京华彬立成科技有限公司 | Target point information mining and searching method and device, electronic equipment and storage medium |
| CN115019976A (en) * | 2022-03-23 | 2022-09-06 | 数魔方(北京)医药科技有限公司 | Medicine information mining method and device, and medicine information query method and device |
| CN114927232A (en) * | 2022-04-29 | 2022-08-19 | 数魔方(北京)医药科技有限公司 | Drug research and development type mining and searching method and device and electronic equipment |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112382362B (en) | 2021-06-29 |
| WO2022095870A1 (en) | 2022-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112382362B (en) | Data analysis method and device for target drugs | |
| Gatesy et al. | Hidden likelihood support in genomic data: can forty-five wrongs make a right? | |
| Stocsits et al. | Accurate and efficient reconstruction of deep phylogenies from structured RNAs | |
| Baele et al. | Bayesian evolutionary model testing in the phylogenomics era: matching model complexity with computational efficiency | |
| Xin et al. | Shifted Hamming distance: a fast and accurate SIMD-friendly filter to accelerate alignment verification in read mapping | |
| Wu et al. | PROPER: comprehensive power evaluation for differential expression using RNA-seq | |
| Si et al. | Model-based clustering for RNA-seq data | |
| Stranneheim et al. | Classification of DNA sequences using Bloom filters | |
| Jalili et al. | Using combined evidence from replicates to evaluate ChIP-seq peaks | |
| Gao et al. | TideHunter: efficient and sensitive tandem repeat detection from noisy long-reads using seed-and-chain | |
| CN112289376B (en) | Method and device for detecting somatic cell mutation | |
| CN114203269B (en) | Anticancer traditional Chinese medicine screening method based on machine learning and molecular docking technology | |
| Tammi et al. | Correcting errors in shotgun sequences | |
| CN112599218A (en) | Training method and prediction method of drug sensitivity prediction model and related device | |
| Polanski et al. | Wigwams: identifying gene modules co-regulated across multiple biological conditions | |
| Junet et al. | CuBlock: a cross-platform normalization method for gene-expression microarrays | |
| Li et al. | Bayesian inference with historical data-based informative priors improves detection of differentially expressed genes | |
| Hampson et al. | Statistical detection of chromosomal homology using shared-gene density alone | |
| Yosef et al. | Improved network-based identification of protein orthologs | |
| CN101886114A (en) | Method for analyzing high-throughput sequencing data based on RMI (Read Mass Index) | |
| CN110211634B (en) | Method for joint analysis of multiple groups of chemical data | |
| Xie et al. | Identification of population-level differentially expressed genes in one-phenotype data | |
| CN103177197A (en) | Differential expression detecting and alternative splicing analyzing method based on high throughput sequencing | |
| Meng et al. | Enrichment constrained time-dependent clustering analysis for finding meaningful temporal transcription modules | |
| Muzio et al. | networkGWAS: A network-based approach to discover genetic associations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |